Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms. (ClearRing)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Active ageing and self-management of health
Action type: SME instrument
Countries involved: Israel
Call: Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2018-01-01
End date: 2018-04-30
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

There are approximately 30 million men worldwide who experience moderate to severe Benign Prostatic Hyperplasia (BPH) symptoms. These symptoms, such as urgent need to urinate, difficulty starting urination, weak stream, or increased frequency of urination, are severe enough to disrupt a patient’s daily lifestyle. Of the 30 million sufferers, an estimated 25% require immediate active treatment. Transurethral Resection of the Prostate (TURP), the current gold standard procedure, is costly, ineffective, and can lead to harsh side effects such as infertility, erectile dysfunction, and bladder irritability, while alpha blockers can lead to weakness, dizziness, and headaches. Therefore, there is a significant unmet need for minimally invasive BPH therapy as a less costly, tolerable, and safe alternative to drugs and surgery. Pro Arc Medical is introducing the ClearRing system, designed to expand the prostate and provide immediate relief of BPH symptoms. Because all of the tools necessary are located within the housing of the elongated shaft, the device can easily be inserted and removed without the need for extraneous procedures. The ClearRing system will bring an immediate cost reduction and time advantage to surgeons and hospitals. The minimally invasive procedure will reduce the range and severity of side effects allowing patients to resume their normal lifestyles potentially twice as fast as the current standard operation procedure. During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Pro Arc will upgrade the ClearRing system, as well as optimize the system in order to allow for two implants to be inserted at the same time during the second phase of innovation project. A clinical trial will then be initiated to obtain ISO 13845 and CE mark.

Keywords: prostate expansion,minimally invasive,benigh prostatic hyperplasia,difficulty urinating,infertility,erectile dysfunction,bladder irritability
Implementation of integrated and innovative Precision Agriculture management strategies to reduce the occurrence of ochratoxins along the vine value chain products: grapes, raisins/currants and wine (OchraVine Control)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Research and innovation staff exchange
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Italy,Greece,Greece,France,France,United Kingdom,United Kingdom
Call: Research and Innovation Staff Exchange (H2020-MSCA-RISE-2017, 2017)
Start date: 2018-01-01
End date: 2023-10-31
Duration (months): 70.0
Total project cost (EUR): 1183500.0
EU funding (EUR): 1183500.0
Participants: 9
Project status: SIGNED

The risk of mycotoxins is a global issue that represents a serious risk for human and animal health. Οchratoxin A (OTA) is a very toxic mycotoxin that constitutes a severe problem for viticulture and taking into account the extreme climatic events that are frequently faced in recent years, the OTA problem is arising in wine and raisins/currants. OchraVine Control project will offer an inexistent innovative, sustainable and integrated smart ICT solution (OchraVine Control DSS) considering fungal, host and environmental indicators that affect OTA contamination along the vine grape-wine value chain. The OchraVine Control DSS will allow prediction and monitoring at pre- and post-harvest level to control Aspergillus infection and OTA contamination in vine cultivation by combining epidemiological data, biological and chemical management strategies, post-havrest technologies and precision agriculture tools. OchraVine Control DSS solution will pursue a field-to-fork approach and will link and translate the information derived from the OchraRisk and OchraDetect predictive map tools and real data obtained during the monitoring controls by the OchraSensor. OchraVine Control DSS tool will be placed in an open access web platform and in combination with data from the OchraRed Integrated Management Strategy will provide risk prediction information (i.e. geographic OTA vine alerts), practical recommended solutions for OTA management and will verify the compliance with legislation requirements in a rapid and cost-effective way. The project will have a multi-actor international approach involving 3 RTDs and 5 SMEs that will exchange skills and knowledge and will all have a vital role in the design of the solutions, implementation, testing, dissemination, communication and economic exploitation.

Keywords: food safety,mycotoxins,ochratoxin a,vine grape wine,disease prediction,monitor,biosensor,desicion support system
Kiwellins in the plant defense against pathogenic invaders (KIWIsome)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Environmental Biology, Ecology and Evolution
Panel description: Ecology, biodiversity, environmental change, evolutionary biology, behavioural ecology, microbial ecology, marine biology, ecophysiology, theoretical developments and modelling
Countries involved: Germany
Call: ERC ADVANCED GRANT (ERC-2020-ADG, 2020)
Start date: 2021-08-01
End date: 2026-07-31
Duration (months): 60.0
Total project cost (EUR): 2344343.0
EU funding (EUR): 2344343.0
Participants: 1
Project status: SIGNED

Plant diseases caused by pathogenic fungi critically affect global food security and plant ecology. How plants defend themselves against pathogenic invaders and the molecular weaponry involved is still far from being complete. Kiwellin proteins (KWL) represent an emerging class of highly diverse proteins with antibody-like properties serving as countermeasures of plants against virulence factors secreted by pathogenic fungi. The aim of this ERC-project is to establish the functional, structural and mechanistic basis enabling this fundamentally new class of proteins in the defense against their pathogenic invaders. Thus, this ERC-proposal might not only offer new perspectives for a future plant engineering (e.g. towards resistance), but also provides a deeper fundamental understanding into the molecular mechanisms, underlying the everlasting arms race between plants and their pathogenic invaders.
Fertility and Mental health: the impact of Assisted Reproductive Technology and fertility intentions on adults’ mental health. (FaMART)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Germany
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-04-21
End date: 2024-04-20
Duration (months): 24.0
Total project cost (EUR): 162806.4
EU funding (EUR): 162806.4
Participants: 1
Project status: CLOSED

In In the last decades, low fertility rates have increasingly been a policy and societal concern. Fertility rates have been coupled to the development of contraceptive and reproductive technologies, which dramatically affect the transition to parenthood. In Western societies, where contraceptive use is widespread, unintended births are now uncommon events associated with early motherhood, family instability and low socioeconomic status. Concomitantly, the utilization of Medically Assisted Reproduction (MAR), which often coincides with delays in childbearing and high socioeconomic resources, has rapidly increased and has revolutionized the way we think about parenthood. Despite growing interest from scholars and policymakers in fertility and MAR, there remains a lack of research on how fertility intentions and the mode of conception affect couples’ mental health longitudinally. By exploiting longitudinal survey data, I will be able, for the first time, to analyse how adults’ mental health changes before, during and after unintended, intended/natural and natural/medically assisted conceptions. Advanced statistical techniques (e.g. ‘distributed’ fixed effects models) will be used to remove the bias introduced by unobserved confounding factors. By examining Swedish Population register data, I will investigate how mental health changes before and after treatment among single women and (both heterosexual and lesbian) couples. The project, which will be hosted at the Max Planck Institute for Demographic Research (Germany), integrates four research areas (sociology, demography, epidemiology and psychology) to produce novel and cutting-edge research on fertility. The aim is to shed light on the effects of fertility intentions and the mode of conception in countries where unplanned births are less common (Germany and Switzerland) and more common (the UK and the US), and where the majority of MAR treatments are funded publicly (the Sweden and Germany) and and privately (U.K.).

Keywords: fertility,assisted reproduction,mental health,longitudinal analysis
WAvelength VErsatile Pulsed Raman FIbre Lasers (WAVEFIL)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2017-01-04
End date: 2019-01-03
Duration (months): 24.0
Total project cost (EUR): 195454.8
EU funding (EUR): 195454.8
Participants: 1
Project status: CLOSED

The primary goal of the WAvelength-VErsatile Pulsed Raman FIbre Lasers (WAVEFIL) project is to train a talented researcher with a strong academic background in laser technology and nonlinear optics, through a research programme focused on developing wavelength-versatile, pulsed, Raman fibre lasers (RFLs) at 1.6 μm–1.8 μm, and their applications for simultaneous dual mid-Infrared (mid-IR) laser generation at 2.7 μm and 4.3 μm in an OPO system. These two mid-IR wavelengths are highly desirable as an atmospheric sensing, since both correspond to the peak absorption of the primary greenhouse gas, CO2. The success of this project will contribute knowledge to the fields of laser science and technology, and establish an internationally leading position for Europe in the industrial applications relevant to gas monitoring, medicine and defence. The Fellow, Dr. J. Liu, will receive substantial training activities in professional knowledge and skills in the field of photonics, material sciences and industrial commercialisation. This will take place at the EU host Aston Institute of Photonic Technologies (AIPT), Aston University (Prof. S. K. Turitsyn), and academic secondments of the University of Mons (UMONS) (Dr. A. A. Fotiadi), Tampere University of Technology (TUT) (Prof. O. Okhotnikov), Imperial College London (IC) (Dr. E. Kelleher) and the industrial partner, ART Photonics (Dr. V. Artjushenko). This training-through-research project will significantly enhance the Fellow’s competence in multidisciplinary research areas, establishing him as a leading figure in photonics research and industry communities. This project will explore the commercialisation of a novel laser system and enable a greater market share for gas monitoring applications. A long-term collaboration between the Fellow and host and co-hosts will be established, ultimately resulting in a new level of high-brilliance laser sources and contributing to the European competiveness in laser technology.

Keywords: fiber laser,stimulated raman scattering,mode locking,nonlinear frequency conversion
Cost-effective transformation of a Highly-Efficient, Advanced, Thermal Ultra-SuperCritical coal-fired power plant into a CHP by retrofitting and integrating an ARBAFLAME biomass upgrading process. (ARBAHEAT)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Theme: Low-cost, low-carbon energy supply
Action type: Innovation actions
Countries involved: Belgium,Norway,Belgium,Norway,Norway,Netherlands,Netherlands,Netherlands,Netherlands
Call: Demonstrate highly performant renewable technologies for combined heat and power (CHP) generation and their integration in the EU's energy system (H2020-LC-SC3-2018-RES-SingleStage, 2018)
Start date: 2018-10-01
End date: 2022-09-30
Duration (months): 48.0
Total project cost (EUR): 26022635.28
EU funding (EUR): 19262647.7
Participants: 14
Project status: SUSPENDED

In the ARBAHEAT project an existing 731 MWe Ultra-SuperCritical coal-fired power plant will be transformed into a biomass-fired Combined Heat and Power plant by repowering with thermally-treated biomass produced on-site. This demonstration encompasses: (1) Transformation into CHP: This will be demonstrated by delivering a minor amount of heat to the on-site biomass treatment process, while envisaging large-volume heat delivery to nearby industry. This will provide renewable local heat, enhancing the overall efficiency of the plant from 46% electricity-only to 70-90% in CHP mode, (2) Biomass feedstock: An integrated thermal pre-treatment process will enable utilisation of diverse sustainable biomass feedstock. This will minimise investment and operating cost while broadening the possibilities in term of geographical feedstock sourcing and quality (3) Biomass pre-treatment: The thermal biomass upgrading process of ARBAFLAME will deliver biomass fuel with handling and milling characteristics approaching that of coal, allowing for retrofitting with minimal adaptations to the existing power plant. The technical capacity of the demonstration plant will allow for maximum flexibility in upscaling the technology for future replication, (4) Integration into power plant: The biomass pre-treatment and heat delivery system will be physically integrated within the existing power plant. Eliminating several cost and energy intensive steps (steam production, pelletizing) will be investigated, towards more cost-effective final design. This demonstration of an integrated very low-costs concept in large-scale energy production will pave the way to subsequent multiplication in commercial industrial projects, thus increasing the EU capacity for renewable power and heat generation. The renewable ARBAHEAT solution therefore has the potential to significantly contribute to the replacement of fossil-fuel in the heat and power sectors and increase the decarbonisation of the energy market.

Keywords: retrofit,steam explosion,biomass,thermal treatment,renewable,cost effective,feedstock,heat,power
Cyber-Physical Intensive Care Medical System for Covid-19 (ICU4Covid)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Action type: Innovation actions
Countries involved: Germany,Germany,Austria,Germany,Israel,Italy,Italy,Greece,Greece,Romania,Latvia,Netherlands,Netherlands,Portugal,Portugal,Portugal,Portugal,Luxembourg
Call: Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels (TRL) (H2020-SC1-PHE-CORONAVIRUS-2020-2-CNECT, 2020)
Start date: 2021-01-01
End date: 2022-12-31
Duration (months): 24.0
Total project cost (EUR): 12464376.96
EU funding (EUR): 10497102.379999999
Participants: 27
Project status: SIGNED

The European health services have well responded to the COVID-19 emerging crisis, especially if and where the intensive care unit (ICU) capacities were sufficient, were prepared and collectively cooperating, sharing knowledge and were able to protect from further spreading of the disease among the healthcare workforce and the patients. Today, only 47% of hospitals have the recommended coverage of intensive care specialists and they are unevenly distributed between centres and periphery. The Cyber-Physical System for Telemedicine and Intensive Care (CPS4TIC) enables existing or new ICU structures to transform and operate as one ICU Hub with one central ICU and connected ICUs in peripheral hospitals. CPS4TIC was used successfully in the first wave of COVID-19 to ensure efficient and effective diagnosis and treatment of COVID-19 patients, while reducing the risk of infection drastically. The CPS4TIC consists of a telemedicine cockpit, telemedicine consoles at each peripheral hospital, a connector platform and smart bedside hubs including robotic arm at the bedsides of both, the central telemonitoring clinics and the peripheral telemonitored hospitals. The ICU Hub operates telemedicine, continuous real-time telemonitoring and bedside smart care environment. The bedside smart care environment reduces the risk of infection for the health workforce significantly both for the central and the peripheral hospitals. ICU4Covid will deploy and test the CPS4TIC at large-scale, in 10 ICU Hubs in Europe, involving more than 30000 patients/year with a coverage of approximately 60 Million citizens.

Keywords: cyberphysical systems,robotics,ai for telemedicine,continuous remote monitoring
Attosecond physics, free electron quantum optics, photon generation and radiation biology with the accelerator on a photonic chip (AccelOnChip)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Fundamental constituents of matter
Panel description: Particle, nuclear, plasma, atomic, molecular, gas, and optical physics
Countries involved: Germany
Call: ERC Advanced Grant (ERC-2019-ADG, 2019)
Start date: 2020-10-01
End date: 2025-09-30
Duration (months): 60.0
Total project cost (EUR): 2498507.5
EU funding (EUR): 2498507.5
Participants: 1
Project status: SIGNED

Resting on our demonstration of laser-driven nanophotonics-based particle acceleration, we propose to build a miniature particle accelerator on a photonic chip, comprising high gradient acceleration and fully optical field-based electron control. The resulting electron beam has outstanding space-time properties: It is bunched on sub-femtosecond timescales, is nanometres wide and coherent. We aim at utilizing this new form of all-optical free electron control in a broad research program with five exciting objectives: (1) Build a 5 MeV accelerator on a photonic chip in a shoebox-sized vessel, (2) Perform ultrafast diffraction with attosecond and even zeptosecond electron pulses, (3) Generate photons on chip at various wavelengths (IR to x-ray), (4) Couple quantum-coherently electron wavepackets and light in multiple interaction zones, and (5) Conduct radiobiological experiments, akin to the new FLASH radiotherapy and Microbeam cell treat-ment. AccelOnChip will enable five science objectives potentially shifting the horizons of today’s knowledge and capabilities around ultrafast electron imaging, photon generation, (quantum) electron-light coupling, and radiotherapy dramatically. Moreover, AccelOnChip promises to democratize accelerators: the accelerator on a chip will be based on inexpensive nanofabrication technology. We foresee that every university lab can have access to particle and light sources, today only accessible at large facilities. Last, AccelOnChip will take decisive steps towards an ultracompact electron beam radiation device to be put into the tip of a catheter, a potentially disruptive radiation therapy device facilitating new treatment forms. AccelOnChip is a cross-disciplinary high risk/high return project combining and benefiting nanophotonics, accelerator science, ultra-fast physics, materials science, coherent light-matter coupling, light generation, and radiology - and is based on my group’s unique expertise acquired in recent years.

Keywords: nanophotonics based particle acceleration,dielectric laser acceleration,accelerator on a chip,attosecond electron pulses,coherent free electron light interaction,photon generation
Discovering how polycomb domains form and function in gene regulation (PolyDomFormFuncReg)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Integrative Biology: from Genes and Genomes to Systems
Panel description: Genetics, epigenetics, genomics and other ‘omics studies, bioinformatics, systems biology, genetic diseases, gene editing, innovative methods and modelling, ‘omics for personalised medicine
Countries involved: United Kingdom
Call: ERC Consolidator Grant (ERC-2015-CoG, 2015)
Start date: 2016-06-01
End date: 2021-05-31
Duration (months): 60.0
Total project cost (EUR): 1999416.0
EU funding (EUR): 1999416.0
Participants: 1
Project status: CLOSED

Polycomb group chromatin modifying systems are essential for normal gene regulation and development, and alterations in their activity are a hallmark of a broad range of cancers. Although the chromatin modifications placed by the two central polycomb protein complexes (PRC1 and PRC2) are well-characterized, how this fascinating system selects its target sites in vivo, and then forms polycomb chromatin domains that are repressive to transcription remains enigmatic. This constitutes the major conceptual gap in our understanding of this essential gene regulatory system. We recently discovered a new pathway that is sufficient in model systems to initiate polycomb chromatin domain formation. Building on this discovery, an ambitious high-risk/high-reward yet hypothesis-driven multidisciplinary approach integrating biochemical, molecular, genomic, and single-cell analyses will be exploited to discover the fundamental principles that underpin polycomb domain formation and subsequently transcriptional repression. Specifically, the three aims of the research programme are to: (i) Discover how the KDM2B/PRC1 complex initiates polycomb domain formation, (ii) Discover how polycomb target sites are selected and polycomb domains formed during normal cell lineage commitment, and (iii) Discover how polycomb domains regulate gene expression. Going well beyond the state-of-the-art, our innovative approaches will lead to major new breakthroughs closing the conceptual gap that currently limits our understanding of how polycomb complexes regulate gene expression, an essential first step towards the possibility of devising strategies for therapeutic intervention in human cancers and other diseases where these systems are perturbed. Furthermore, support from the ERC in tackling these important problems will allow me to recruit the talented individuals necessary to achieve our objectives and consolidate my position as an emerging leader in the field.